Ticker
ENGN
1 report from NewsMV on ENGN, newest first.
enGene Therapeutics (ENGN) targets Q4 BLA initiation for detalimogene as LEGEND pivotal data and FDA meeting converge
Regulatory
Sep 8, 2026
← All tickers